Defining the effects of an inhaled corticosteroid and long-acting β-agonist on therapeutic targets

Allergy and Asthma Proceedings

Volumn 24, Issue 2, 2003, Pages 85-89

  Settipane, Russell A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; SALMETEROL; THEOPHYLLINE;

ALLERGIC RHINITIS; ASTHMA; BRONCHOSPASM; CATARACT; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GLAUCOMA; GROWTH RETARDATION; HUMAN; LUNG BIOPSY; MAINTENANCE DRUG DOSE; MUSCLE FUNCTION; PATHOPHYSIOLOGY; PATIENT; PATIENT COMPLIANCE; PHYSICIAN; RECURRENT DISEASE; RESPIRATORY TRACT INFLAMMATION; SIDE EFFECT; SKIN BRUISING; SMOOTH MUSCLE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0041919375     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma - update on selected topics 2002. National Asthma Education and Prevention Program Expert Panel Report. NIH publication 02-5075, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute, Bethesda MD, 2002.
2. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from broncho-constriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161:1720-1745, 2000.
3. Green SA, and Nelson HS. Adrenergic agents. In Allergy Principles & Practice. Middleton E, Reed CE, Ellis E, et al. (Eds). St. Louis, MO: Mosby-Year Book, Inc., 571-576, 1998.
4. Schleimer RP. Glucocorticoids. In Allergy Principles & Practice. Middleton E, Reed CE, Ellis E, et al. (Eds). St. Louis, MO: Mosby-Year Book, Inc., 638-660, 1998.
5. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150:17-22, 1994.
6. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization from asthma. JAMA 277:887-891, 1997.
7. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332-336, 2000.
8. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta-2 agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 325:388-392, 1991.
9. Agertoft L, and Pedersen S.. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 88:373-381, 1994.
10. Selroos O, Pietinalho A, Lofroos AB, and Riska H. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest 108: 1228-1234, 1995.
11. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 327:1420-1425, 1992.
12. D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271:1412-1416, 1994.
13. Chong LK, Cooper E, Vardey CJ, and Peachell PT. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 123:1009-1015, 1998.
14. Bolton PB, Lefevre P, and McDonald DM. Salmeterol reduces early and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 155:1428-1435, 1997.
15. Proud D, Reynolds CJ, Lichtenstein LM, et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 28:868-875, 1998.
16. Matz J, Kalberg C, Emmett A, et al. The combination of salmeterol and low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 105:162S, 2000.
17. Knox AJ. The scientific rational of combining inhaled corticosteroids and long acting beta-2 adrenoceptor agonists. Curr Pharm Des 8:1863-1869, 2002.
18. Roth M, Johnson PRA, Rudiger JJ, et al. Interaction between glucocorticoids and beta-2 agonists on bronchial airway smooth muscle cells through synchronised cellular signaling. Lancet 360:1293-1299, 2002.
19. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 113:587-592, 1998.
20. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159: 941-955, 1999.
21. Simon RA. Update on inhaled corticosteroids: safety, compliance, and new delivery systems. Allergy Asthma Proc 20:161-165, 1999.
22. Roy A, Leblanc C, Paquette L, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Eur Respir J 9:226-231, 1996.
23. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399-1403, 2000.
24. Garbe E, Suissa S, and Lelorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 280:539-543, 1998.
25. Mitchell P, Cumming RG, and Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 106:2301-2306, 1999.
26. Wolthers OD, and Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 68:673-676, 1993.
27. Greening AP, Wind P, Northfield M, and Shaw G. Added salmeterol versus higher dose corticosteroid therapy in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224, 1994.
28. Woolcock A, Lundback B, Ringdal N, and Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of the dose of inhaled steroids. Am J Respir Crit Care Med 153: 1481-1488, 1996.
29. Shrewsbury S, Pyke S, and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 320:1368-1373, 2000.
30. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroids plus montelukast. J Allergy Clin Imunol 106:1088-1095, 2000.
31. Fjellbirkeland L, Gulsvik A, and Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained release theophylline in patients with reversible airways disease. Respir Med 88:599-607, 1994.
32. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health pub no 91-3642. Bethesda, MD, 1991.